Sanara Medtech Inc. (SMTI) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Sanara Medtech Inc. is a medical technology company focused on surgical solutions, specifically soft tissue repair and bone fusion products. During the quarter, the Company made a significant strategic shift by discontinuing its Tissue Health Plus (THP) segment. Consequently, the Company now reports as a single operating segment (Sanara Surgical). The THP segment, including the recently acquired CarePICS technology, has been classified as discontinued operations due to persistent losses and a lack of investor interest.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Revenue (Continuing Ops) | $26.33 million | $21.67 million | $75.57 million | $60.37 million |
| Gross Profit | $24.46 million | $19.68 million | $69.93 million | $54.48 million |
| Gross Margin | 92.9% | 90.8% | 92.5% | 90.2% |
| Operating Income (Continuing Ops) | $2.94 million | $0.78 million | $6.25 million | ($1.00 million) |
| Net Income (Continuing Ops) | $0.83 million | ($0.18 million) | $0.71 million | ($2.87 million) |
| Net Loss (Total, incl. Discontinued) | ($30.41 million) | ($2.88 million) | ($35.96 million) | ($8.21 million) |
| Adjusted EBITDA | $4.91 million | $2.56 million | $12.32 million | $5.10 million |
| Cash and Equivalents | $14.94 million | As of Sept 30, 2025 | ||
| Long-Term Debt | $45.09 million | As of Sept 30, 2025 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue from continuing operations increased 22% year-over-year in Q3 and 25% year-over-year for the nine months ended September 30, 2025. This growth was driven by increased sales of soft tissue repair products (CellerateRX Surgical, BIASURGE) and bone fusion products.
- Discontinued Operations Impact: The Company recorded a net loss from discontinued operations of $31.25 million for Q3 2025, primarily due to a $26.47 million asset impairment charge related to the write-off of THP technology, intangible assets, and internal use software. This charge significantly impacted the consolidated net loss.
- Profitability: Continuing operations turned profitable in Q3 2025 ($0.83M net income) compared to a loss in the prior year, driven by revenue growth outpacing expense increases. However, total net loss remains high due to the discontinued operations write-off.
- Debt Expansion: Long-term debt increased from $30.69 million (Dec 31, 2024) to $45.09 million (Sept 30, 2025). This reflects a third borrowing of $12.25 million under the CRG Term Loan in March 2025.
- Investments: The Company increased its investment in equity securities, primarily through milestone payments to Biomimetic Innovations Limited (BMI), bringing the total carrying value to $12.59 million.
Guidance, Outlook, and Risks
- Outlook: Management expects cash on hand ($14.9M) combined with operating cash flows and available debt capacity ($12.25M remaining on the CRG Term Loan) to fund operations for at least the next 12 months. The Company anticipates cash outlays of $1.5M to $2.5M in Q4 2025 to wind down the THP segment.
- Debt Covenants: The CRG Term Loan requires maintaining minimum annual revenue of $75.0 million for the 2025 fiscal year. The Company reported $75.57 million in revenue for the nine months ended September 30, 2025, and stated it is in compliance with all covenants as of the reporting date.
- Risks: Key risks include the ability to meet future capital requirements, compliance with debt obligations, and the successful commercialization of new products like the BMI OsStic technology. The Company also faces risks related to the winding down of the THP segment and potential further impairments.
- Unusual Items: The $26.47 million impairment charge is a non-cash item specific to the discontinued THP segment and does not reflect the performance of the core Sanara Surgical business.
Investor Verification Checklist
- Debt Covenant Compliance: Verify that the Company meets the $75.0 million annual revenue covenant for the full 2025 fiscal year to avoid default on the CRG Term Loan.
- THP Wind-Down Costs: Monitor Q4 2025 cash flow to ensure the projected $1.5M-$2.5M wind-down costs for the THP segment do not exceed estimates.
- Continuing Operations Margins: Confirm that the high gross margins (~92%) in continuing operations are sustainable as the Company scales sales of CellerateRX and BIASURGE.
- BMI Milestone Payments: Track future capital commitments to BMI, as the Company has agreed to contribute up to an additional €4.0 million upon achieving specific milestones.
- Impairment Finality: Ensure no further material impairments are recorded related to the THP segment or other intangible assets in future periods.